NASDAQ:MLYS Mineralys Therapeutics Q2 2026 Earnings Report $27.35 +0.36 (+1.33%) Closing price 08/7/2026 04:00 PM EasternExtended Trading$27.33 -0.02 (-0.07%) As of 08/7/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mineralys Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.55Beat/MissN/AOne Year Ago EPSN/AMineralys Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMineralys Therapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeAfter Market ClosesConference Call DateTuesday, August 11, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Mineralys Therapeutics Earnings HeadlinesMineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026August 4, 2026 | markets.businessinsider.comMineralys Therapeutics to Report Second Quarter 2026 Financial Results on August 11August 4, 2026 | quiverquant.comQSpaceX Earnings Crash: The End of the AI Bubble?Jeremy Grantham calls today's market the biggest investment bubble in American history, and Ray Dalio agrees. SpaceX's latest earnings disappointed, and Morgan Stanley and Goldman Sachs now warn of a much bigger crisis unfolding over the next decade. TradeSmith CEO Keith Kaplan says there's another side to the AI story most people aren't discussing.August 8 at 1:00 AM | TradeSmith (Ad)Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)July 27, 2026 | globenewswire.comA Mineralys Insider Banked a $557,000 Options Gain Before a December FDA DateJuly 16, 2026 | finance.yahoo.comIs Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential?July 2, 2026 | insidermonkey.comSee More Mineralys Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mineralys Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your email. Email Address About Mineralys TherapeuticsMineralys Therapeutics (NASDAQ:MLYS), a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.View Mineralys Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Quantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusDatadog’s Drop Says More About Expectations Than EarningsD-Wave's Quantum Breakthrough Couldn't Save QBTS From a Sell-OffAppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay BullishUber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
